 Dana-Farber Cancer Institute ( DFCI) ALL Consortium Protocol 05-001 tested a new risk stratification system in children and adolescents with newly diagnosed acute lymphoblastic leukemia<disease> ( ALL). At study entry , B-ALL patients were classified as standard risk ( SR) or high risk ( HR) based on age , white blood cell ( WBC) count , and central nervous system status<symptom>. After achieving complete remission ( CR) , patients with high end-induction minimal residual disease<disease> ( MRD) ( â‰¥ 10